SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech for less than cash value -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (550)12/19/2019 1:09:10 PM
From: BulbaMan  Respond to of 684
 
Hi Rick, I’ve met ADRO’s CEO, Steve Isaacs, a number of times and think he’s a good guy. At 71, my intuition is he’ll try to retire on a high note by using ADRO’s cash to get a piece of another drug with great potential (either via merger or a partnership).
As for their anti-APRIL drug, Steve was of course optimistic when I spoke to him about a month ago. But my bet on ADRO is much more on him using the $230 million in cash to do a smart deal.
Peace & good health,
Bulba



To: scaram(o)uche who wrote (550)12/30/2019 4:18:14 PM
From: scaram(o)uche  Respond to of 684
 
Morgan Stanley discloses 8.8% torc position, joining Armistice Capital (9.6%) as institutions coming on board after the crash. Up 12% after hours on MS disclosure.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News